Recursion Pharmaceuticals, Inc. RXRX Indefinite-Lived Intangible Assets, Gross
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross?
- Recursion Pharmaceuticals, Inc. (RXRX) reported indefinite-lived intangible assets, gross of $135.55M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross increased by 2.1% year-over-year, from $132.74M to $135.55M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets, gross has grown at a 173.4% compound annual growth rate (CAGR), from $904K to $138.02M.